


## *FIGS. 1A-1E*





## *FIGS. 2A-2D*



## *FIGS. 3A-3B*




## *FIGS. 4A-4B*



*FIGS. 5A-5K*





*FIG. 6*




*FIG. 7*



CD4+
% of CD4+
IC
anti-LAP
CD4+INFγ+
% of CD4+INFγ+
IC
anti-LAP
CD4+CTLA4+
% of CD4/CTLA4
IC
anti-LAP
CD4+PD1+
% of CD4+PD1+
IC
anti-LAP
IL17
% of CD4/IL17
IC
anti-LAP

*FIG. 8*



CD8+
% of CD8+
IC
anti-LAP
CD8+INFγ+
% of CD8+INFγ+
IC
anti-LAP
CD8+CTLA4+
% of CD8/CTLA4
IC
anti-LAP
CD8+PD1+
% of CD8+PD1+
IC
anti-LAP

*FIG. 9*



NK+
% of NK+
IC
anti-LAP
NK+GRZB+
% of NK+GRZB+
IC
anti-LAP
NK+INFγ+
% of NK+INFγ+
*
IC
anti-LAP

*FIG. 10*



LN
CPM
2500
2000
1500
1000
500
0
IC
anti-LAP

*FIG. 11*



LN IFNg
IFNg (pg/ml)
2000
1500
1000
500
0
IC
anti-LAP
LN TGFb total
TGFb (pg/ml)
2000
1500
1000
500
0
IC
anti-LAP
LN TGFb active
TGFb (pg/ml)
800
600
400
200
0
IC
anti-LAP

*FIG. 12*



- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
1.55
0.208
0.263
0.243
0.214
LAP
CD4
CD4/LAP
% of CD4+LAP+
FMO
a-LAP
+block
FMO

*FIG. 13*



- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
35.1
0.661
0.19
0.331
0.907
LAP
CD16
CD14+CD16+
% of LAP+ Cells
FMO
a-LAP
+block
FMO

*FIG. 14*



- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
73.3
6.31
0.0867
0.0633
0.0529
LAP
CD14
CD14+CD16-
% of CD14+LAP+
FMO
a-LAP
+block
FMO

*FIG. 15*



- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
FMO
72.2
5.79
72.2
0.101
0.0634
0.0528

*FIG. 16*



- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
FMO
6.06
1.97
0.196
0.799
1.1
LAP
CD11c

*FIG. 17*



7AAD
Lin
CD11c
CD123

*FIG. 18*





- blocking a-LAP
+ blocking a-LAP
a-LAP
IC
FMO
4.8
0.668
0.809
0.305
0.787
LAP
SSC

***FIG. 19***





*SC GBM Model*

***FIG. 20***





*SC GBM Model*

***FIG. 21***





*SC GBM Model*

***FIG. 22***





*SC GBM Model*

***FIG. 23***





*SC GBM Model*

***FIG. 24***




*SC GBM Model*

***FIG. 25***




*SC GBM Model*

***FIG. 26***






***FIG. 27***





*SC GBM Model*

***FIG. 28***





*SC GBM Model*

**FIG. 29**





*SC GBM Model*

**FIG. 30**





*Naïve mice*

***FIG. 31***





*Naïve mice*

***FIG. 32***





*SC GBM Model*

***FIG. 33***





*SC GBM Model*

***FIG. 34***





*SC GBM Model*

***FIG. 35***





*SC GBM Model*

***FIG. 36***





*SC GBM Model*

***FIG. 37***





*SC GBM Model*

***FIG. 38***





*INC GBM Model*

## *FIG. 39*





*INC GBM Model*

## *FIGS. 40A-40B*





*da Cunha AP, et al. Int Immunol, 2014*

***FIG. 41***





*INC GBM Model*

***FIG. 42***





*INC GBM Model*

***FIG. 43***





*INC GBM Model*

***FIG. 44***





*INC GBM Model*

***FIG. 45***





*INC GBM Model*

***FIG. 46***





*INC GBM Model*

***FIG. 47***





*INC GBM Model*

***FIG. 48***





*INC GBM Model*

***FIG. 49***




*INC GBM Model*

***FIG. 50***




*B16-OVA Model*

**FIG. 51**


huLAP1
moLAP1
huLAP3
moLAP3
huLAP2
moLAP2

**FIG. 52**


huLAP1
huLAP2
huLAP3


**FIG. 53**


moLAP1 lstcktidmelvkrkrieairgqilsklrlasppsqgevppgplpeavlalynstrdrva
moLAP2 lstcstldmdqfmrkrieairgqilsklkltsppedy-pepdevppevisiynstrdllq
moLAP3 lstcttldfghikkkrveairgqilsklrltsppeps-v-mthvpyqvlalynstrelle
moLAP1 gesad------pepepeadyyakevtrvlmvdrn----naiyektkdishsiymffntsdir
moLAP2 ekasrraaacererseeyyakevykidmpshlpsenaipptfyrpyfrivr-fdvstm-
moLAP3 emhgereegctqetseseyyakeihkfdmiqglaehnelavcpkgitskvfr-fnvssv-
moLAP1 eavpeppllsraelrlqrlks-----sveqhvelyqkysn-------nswrylgnrlltptdt
moLAP2 --eknasnlvkaefrvfrlqnpkarvaeqrielyqilkskdltsptqryidskvvktrae
moLAP3 --ekngtnlfraefrvlrvpnpsskrteqrielfqilrpdeh-iakqryiggknlptrgt
moLAP1 pewlsfdvtgvvrqwlnqgdgiqgfrfsahcscdskdnk-----------lh----veing
moLAP2 gewlsfdvtdavqewlhhkdrnlgfkislhcpcctfvpsnnyiipnkseelearfagidg
moLAP3 aewlsfdvtdtvrewllrresnlgleisihcpchtfqpngd-ilenvhevmeikfkgvdn
moLAP1 ispkrrgdlgtih--------dmnrpflllmatpleraqhlhssrhrr--
moLAP2 tstyasgdqktikstrkktsgktphlllmllpsyrlesqqssrrkkr-
moLAP3 eddhgrgdlgrlk----kqkdhhnphlilmmipphrldspgqgsqrkkr


**FIG. 54**


huProTGFb1 mppsglrllpllllpllwllvltpgrpaaglstcktidmelvkrkrieairgqilsklrla
moProTGFb1 mppsglrllpllipwllvltpgrpaaglstcktidmelvkrkrieairgqilsklrla
huProTGFb3 ----------mkmhlqralvvlallafatvslslstcttldfghikkkrveairgqilsklrlt
moProTGFb3 ----------mkmhlqralvvlallslatislslstcttldfghikkkrveairgqilsklrlt
huProTGFb2 ----------mhy-cvlsafllhlvtvslslstcatldmdqfmrkrieairgqilsklklt
moProTGFb2 ----------mhy-cvlstfllhlvpvslslstcatldmdqfmrkrieairgqilsklklt
huProTGFb1 sppsqgevppgplpeavlalynstrdrvagesae------pepepeadyyakevtrvlmve
moProTGFb1 sppsqgevppgplpeavlalynstrdrvagesad------pepepeadyyakevtrvlmvd
huProTGFb3 sppept-v-mthvpyqvlalynstrelleemhgereegctqentseeyyakeihkfdmiq
moProTGFb3 sppeps-v-mthvpyqvlalynstrelleemhgereegctqetseseyyakeihkfdmiq
huProTGFb2 sppedy-pepeevppevisiynstrdllqekasrrsaacererseeyyakevykidmpp
moProTGFb2 sppedy-pepdevppevisiynstrdllqekasrrsaacererseeyyakevykidmps
huProTGFb1 thneiydk----------------------------------------fkqsthsiymffntselreav
moProTGFb1 rnnaiyek----------------------------------------tkdishsiymffntsdireav
huProTGFb3 glaehnela----------------------------------------pk----gitskv-fsfnvssv----e
moProTGFb3 glaehnela----------------------------------------pk----gitskv-fsfnvssv----e
huProTGFb2 ffpseteqpvvttpagsvgslcerqaqvlcgyldaspptfyrpyfri-vrfdvsam----e
moProTGFb2 hlpse----------------------------------------naipptfyrpyfri-vrfdvatm----e
huProTGFb1 pepvllsraelrllrlkl-----kveqhvelyqkysn-------nswrylsnrllapsdspew
moProTGFb1 peppllsraelrlqrlks-----sveqhvelyqkysn-------nswrylgnrlltptdtpew
huProTGFb3 knstnlfraefrvlrvpngsskrteqrielfqilrpdeh-iakqryiggknlptrgtaew
moProTGFb3 knptnlfraefrvlrvpngsskrteqrielfqilrpdeh-iakqryiggknlptrgtaew
huProTGFb2 knaanlvkaefrvfrlqnpkarvpeqrielyqilkskdltsptqryidskvvktraegew
moProTGFb2 knaanlvkaefrvfrlqnpkarvaeqrielyqilkskdltsptqryidskvvktraegew
huProTGFb1 lsfdvtgvvrqwlsrqgeiegfrlsahcscdsrdntl----------q----vdingftt
moProTGFb1 lsfdvtqvvrqwlnqgdgiqgfrfsahcscdskdnkl----------h----veingisp
huProTGFb3 lsfdvtdtvrewllrresnlgleisihcpchtfqpngd-ilenihevmeikfkgvdnedd
moProTGFb3 lsfdvtdtvrewllrresnlgleisihcpchtfqpngd-ilenvhevmeikfkgvdnedd
huProTGFb2 lsfdvtdavhewlhhkdrnlgfkislhcpcctfvpsnnyiipnkseelearfagidgtst
moProTGFb2 lsfdvtdavqewlhhkdrnlgfkislhcpcctfvpsnnyiipnkseelearfagidgtst
huProTGFb1 grrgdlatih--------gmnrpflllmatpleraqh---lqssrhrraldtnycfsstekne
moProTGFb1 krrgdlgtih--------dmnrpflllmatpleraqh---lhssrhrraldtnycfsstekne
huProTGFb3 hgrgdlgrlk----kqkdhhnphlilmmipphrldspgqgsqrkkraldtnycfrnleenn
moProTGFb3 hgrgdlgrlk----kqkdhhnphlilmmipphrldspgqgsqrkkraldtnycfrnleenc
huProTGFb2 ytsqdqktikstrkknsgktphlllmllpsyrlesq-qtnsrrkkraldasycfrnvqdnc
moProTGFb2 yasqdqktikstrkktsgktphlllmllpsyrlesq-qssrrkkraldasycfrnvqdnc
huProTGFb1 cvrqlyidfrkdlgwkwihepkgyhanfclgpcpyiwsldtqyskvlalynqhngasaa
moProTGFb1 cvrqlyidfrkdlgwkwihepkgyhanfclgpcpyiwsldtqyskvlalynqhngasaa
huProTGFb3 cvrplyidfrqdlgwkwvhepkgyyanfcsgpcpyirsadtthstvlglyntlnpeaaas
moProTGFb3 cvrplyidfrqdlgwkwvhepkgyyanfcsgpcpyirsadtthstvlglyntlnpeaaas
huProTGFb2 clrplyidfkrdlgwkwihepkgynanfcagacpylwssdtqhsrvlslyntlnpeaasa
moProTGFb2 clrplyidfkrdlgwkwihepkgynanfcagacpylwssdtqhtkvlslyntlnpeaasa
huProTGFb1 pccvpqalelplvyyvgrkpkveqlsnmivrsckcs
moProTGFb1 pccvpqalelplvyyvgrkpkveqlsnmivrsckcs
huProTGFb3 pccvpqdlelplilyyvgrtpkveqlsnmvvksckcs
moProTGFb3 pccvpqdlelplilyyvgrtpkveqlsnmvvksckcs
huProTGFb2 pccvsqdlelplilyysgntpkieqlsnmivksckcs
moProTGFb2 pccvsqdlelplilyysgntpkieqlsnmivksckcs


## *FIGS. 55A-55N*





## *FIGS. 56A-56B*




## FIGS. 57A-57J




## FIGS. 58A-58D



## FIGS. 59A-59E




## FIGS. 60A-60F





***FIG. 61***




***B16-OVA Model***

***FIG. 62***




*FIG. 63*





AML
TGF-β1
TSP-1
Bladder Carcinoma
TGF-β1
TSP -1
Stomach Adenocarcinoma
TGF-β1
GARP
% of Survival
Survival (months)

*FIG. 64*


TGF-β (pg/ml)
350
300
250
200
150
100
50
0
**
**
** **
No Treatment
Isotype Control
TW4-2C9
TW4-13B12
TW4-8F10
TW4-3H6
TW4-16F4
TW4-1E1
TW4-1G12
TW4-3G5
TW4-6H10
TW7-7H4
TW7-28G11
Treatment

## FIG. 65


Anti-LAP (28G11 clone)
Naive
CD61
CD41
76.0%
79.8%
% of CD41+CD61+
Naive
Anti-LAP
CD62P
2.91%
2.74%
FSC (parental gate CD41+CD61+)
% of CD62P+ platelets
Naive
Anti-LAP

## FIG. 66




huProTGFb1 1 MPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIR 50
moProTGFb1 1 MPPSGLRLLPLLLPLPWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIR 50
huProTGFb1 51 GQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPE 100
moProTGFb1 51 GQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESADPEPEPE 100
huProTGFb1 101 ADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLL 150
moProTGFb1 101 ADYYAKEVTRVLKVDRNNAIYEKTKDISHSIYMFFNTSDIREAVPEPPLL 150
huProTGFb1 151 SRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDV 200
moProTGFb1 151 SRAELRLQRLKSSVEQHVELYQKYSNNSWRYLGNRLLTPTDTPEWLSFDV 200
huProTGFb1 201 TGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATI 250
moProTGFb1 201 TGVVRQWLNQGDGIQGFRFSAHCSCDSKDNKLHVEINGISPKRRGDLGTI 250
huProTGFb1 251 HGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYI 300
moProTGFb1 251 HDMNRPFLLLMATPLERAQHLHSSRHRRALDTNYCFSSTEKNCCVRQLYI 300
huProTGFb1 301 DFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGA 350
moProTGFb1 301 DFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGA 350
huProTGFb1 351 SAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS 390
moProTGFb1 351 SASPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS 390
LAP
TGF-β

***FIG. 67***




*INC GBM Model (brain)*